BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 15930038)

  • 21. Molecular diagnostic applications of DNA methylation technology.
    Cottrell SE
    Clin Biochem; 2004 Jul; 37(7):595-604. PubMed ID: 15234241
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications.
    Sigalotti L; Fratta E; Coral S; Cortini E; Covre A; Nicolay HJ; Anzalone L; Pezzani L; Di Giacomo AM; Fonsatti E; Colizzi F; Altomonte M; Calabrò L; Maio M
    J Cell Physiol; 2007 Aug; 212(2):330-44. PubMed ID: 17458893
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Transcriptional silencing of hedgehog-interacting protein by CpG hypermethylation and chromatic structure in human gastrointestinal cancer.
    Taniguchi H; Yamamoto H; Akutsu N; Nosho K; Adachi Y; Imai K; Shinomura Y
    J Pathol; 2007 Oct; 213(2):131-9. PubMed ID: 17724792
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Epigenetic alterations in gastric carcinogenesis.
    Choi IS; Wu TT
    Cell Res; 2005 Apr; 15(4):247-54. PubMed ID: 15857579
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Developments in cancer management by innovative genomics. 2006 report of the National Cancer Consortium].
    Tímár J; Kásler M; Kátai J; Soós M; Mathiasz D; Romány A; Patthy L; Kovács G; Józsa A; Szilák L; Forrai T
    Magy Onkol; 2006; 50(4):349-59. PubMed ID: 17216011
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The role of cell-free circulating DNA in the diagnosis and prognosis of prostate cancer.
    Ellinger J; Müller SC; Stadler TC; Jung A; von Ruecker A; Bastian PJ
    Urol Oncol; 2011; 29(2):124-9. PubMed ID: 19762255
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Epigenetic profiles distinguish malignant pleural mesothelioma from lung adenocarcinoma.
    Goto Y; Shinjo K; Kondo Y; Shen L; Toyota M; Suzuki H; Gao W; An B; Fujii M; Murakami H; Osada H; Taniguchi T; Usami N; Kondo M; Hasegawa Y; Shimokata K; Matsuo K; Hida T; Fujimoto N; Kishimoto T; Issa JP; Sekido Y
    Cancer Res; 2009 Dec; 69(23):9073-82. PubMed ID: 19887624
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Detection of aberrant promoter CpG islands hypermethylation of GSTP1 in human primary hepatocellular carcinomas].
    Wang JH; Qin Y; Li B; Sun ZL; Sun ZF; Guan QL
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2005 Sep; 36(5):686-8. PubMed ID: 16235538
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Aberrant de novo methylation of the p16INK4A CpG island is initiated post gene silencing in association with chromatin remodelling and mimics nucleosome positioning.
    Hinshelwood RA; Melki JR; Huschtscha LI; Paul C; Song JZ; Stirzaker C; Reddel RR; Clark SJ
    Hum Mol Genet; 2009 Aug; 18(16):3098-109. PubMed ID: 19477956
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The emerging roles of DNA methylation in the clinical management of prostate cancer.
    Perry AS; Foley R; Woodson K; Lawler M
    Endocr Relat Cancer; 2006 Jun; 13(2):357-77. PubMed ID: 16728568
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Detection of aberrant methylation of four genes in plasma DNA for the detection of breast cancer.
    Hoque MO; Feng Q; Toure P; Dem A; Critchlow CW; Hawes SE; Wood T; Jeronimo C; Rosenbaum E; Stern J; Yu M; Trink B; Kiviat NB; Sidransky D
    J Clin Oncol; 2006 Sep; 24(26):4262-9. PubMed ID: 16908936
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Epigenetic silencing of 14-3-3sigma in cancer.
    Lodygin D; Hermeking H
    Semin Cancer Biol; 2006 Jun; 16(3):214-24. PubMed ID: 16698281
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Promoter hypermethylation of the SFRP2 gene is a high-frequent alteration and tumor-specific epigenetic marker in human breast cancer.
    Veeck J; Noetzel E; Bektas N; Jost E; Hartmann A; Knüchel R; Dahl E
    Mol Cancer; 2008 Nov; 7():83. PubMed ID: 18990230
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CpG island hypermethylation in cell-free serum DNA identifies patients with localized prostate cancer.
    Ellinger J; Haan K; Heukamp LC; Kahl P; Büttner R; Müller SC; von Ruecker A; Bastian PJ
    Prostate; 2008 Jan; 68(1):42-9. PubMed ID: 18004747
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Epigenetics of lung cancer.
    Bowman RV; Yang IA; Semmler AB; Fong KM
    Respirology; 2006 Jul; 11(4):355-65. PubMed ID: 16771905
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The epigenetics of oral cancer.
    Shaw R
    Int J Oral Maxillofac Surg; 2006 Feb; 35(2):101-8. PubMed ID: 16154320
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Epigenetic changes in solid and hematopoietic tumors.
    Toyota M; Issa JP
    Semin Oncol; 2005 Oct; 32(5):521-30. PubMed ID: 16210093
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The fundamental role of epigenetics in hematopoietic malignancies.
    Galm O; Herman JG; Baylin SB
    Blood Rev; 2006 Jan; 20(1):1-13. PubMed ID: 16426940
    [TBL] [Abstract][Full Text] [Related]  

  • 39. DNA methylation markers of surfactant proteins in lung cancer.
    Lin Z; Thomas NJ; Bibikova M; Seifart C; Wang Y; Guo X; Wang G; Vollmer E; Goldmann T; Garcia EW; Zhou L; Fan JB; Floros J
    Int J Oncol; 2007 Jul; 31(1):181-91. PubMed ID: 17549420
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Epigenetic changes in cancer.
    Grønbaek K; Hother C; Jones PA
    APMIS; 2007 Oct; 115(10):1039-59. PubMed ID: 18042143
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.